Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Raab MS, Weinhold N, Kortüm KM, Krönke J, Fenk R, Weisel K, Podola L, Bertsch U, Brobeil A, Mersi J, Huhn S, Arlinghaus R, Hundemer M, Bohl SR, Mai EK, Schub N, Waldschmidt J, Bassermann F, Müller-Tidow C, Heuck C, Sakabedoyan C, Khan J, Ershova E, Koster BD, Engelhardt M, Hänel M, Salwender H, Teipel R, Goldschmidt H, Einsele H, Rasche L, GMMG-HD10/DSMM-XX (MajesTEC-5) investigators

Open source

DOI: 10.1038/s41591-026-04471-x
Published: 2026 Jul
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04471-x,
  title = {Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.},
  author = {Raab MS and Weinhold N and Kortüm KM and Krönke J and Fenk R and Weisel K and Podola L and Bertsch U and Brobeil A and Mersi J and Huhn S and Arlinghaus R and Hundemer M and Bohl SR and Mai EK and Schub N and Waldschmidt J and Bassermann F and Müller-Tidow C and Heuck C and Sakabedoyan C and Khan J and Ershova E and Koster BD and Engelhardt M and Hänel M and Salwender H and Teipel R and Goldschmidt H and Einsele H and Rasche L and GMMG-HD10/DSMM-XX (MajesTEC-5) investigators},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04471-x},
  url = {https://doi.org/10.1038/s41591-026-04471-x}
}

RIS

TY  - JOUR
TI  - Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
AU  - Raab MS
AU  - Weinhold N
AU  - Kortüm KM
AU  - Krönke J
AU  - Fenk R
AU  - Weisel K
AU  - Podola L
AU  - Bertsch U
AU  - Brobeil A
AU  - Mersi J
AU  - Huhn S
AU  - Arlinghaus R
AU  - Hundemer M
AU  - Bohl SR
AU  - Mai EK
AU  - Schub N
AU  - Waldschmidt J
AU  - Bassermann F
AU  - Müller-Tidow C
AU  - Heuck C
AU  - Sakabedoyan C
AU  - Khan J
AU  - Ershova E
AU  - Koster BD
AU  - Engelhardt M
AU  - Hänel M
AU  - Salwender H
AU  - Teipel R
AU  - Goldschmidt H
AU  - Einsele H
AU  - Rasche L
AU  - GMMG-HD10/DSMM-XX (MajesTEC-5) investigators
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04471-x
UR  - https://doi.org/10.1038/s41591-026-04471-x
ER  -

APA

MS, R., N, W., KM, K., J, K., R, F., K, W., L, P., U, B., A, B., J, M., S, H., R, A., M, H., SR, B., EK, M., N, S., J, W., F, B., C, M., C, H., C, S., J, K., E, E., BD, K., M, E., M, H., H, S., R, T., H, G., H, E., L, R., & investigators, G. (. (2026). Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04471-x

Source records

pubmed · retrieved 2026-09-26T19:45:02.578Z